|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bamias A, Psaltopoulou T, Sotiropoulou M,
Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A,
Vlahos G and Dimopoulos MA: Mucinous but not clear cell histology
is associated with inferior survival in patients with advanced
stage ovarian carcinoma treated with platinum-paclitaxel
chemotherapy. Cancer. 116:1462–1468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matsuzaki S, Yoshino K, Ueda Y, Matsuzaki
S, Kakuda M, Okazawa A, Egawa-Takata T, Kobayashi E and Kimura T:
Potential targets for ovarian clear cell carcinoma: A review of
updates and future perspectives. Cancer Cell Int. 15:1172015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Crotzer DR, Sun CC, Coleman RL, Wolf JK,
Levenback CF and Gershenson DM: Lack of effective systemic therapy
for recurrent clear cell carcinoma of the ovary. Gynecol Oncol.
105:404–408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sugiyama T, Kamura T, Kigawa J, Terakawa
N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical
characteristics of clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Itamochi H, Kigawa J and Terakawa N:
Mechanisms of chemo-resistance and poor prognosis in ovarian clear
cell carcinoma. Cancer Sci. 99:653–658. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Smith RA, Manassaram-Baptiste D, Brooks D,
Doroshenk M, Fedewa S, Saslow D, Brawley OW and Wender R: Cancer
screening in the United States, 2015: A review of current American
cancer society guidelines and current issues in cancer screening.
CA Cancer J Clin. 65:30–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin LL, Huang HC and Juan HF: Revealing
the molecular mechanism of gastric cáncer marker annexin A4
incancer cell proliferation using exon arrays. PLoS One.
7:e446152012. View Article : Google Scholar
|
|
9
|
Huang HL, Yao HS, Wang Y, Wang WJ, Hu ZQ
and Jin KZ: Proteomic identification of tumor biomarkers associated
with primary gallbladder cancer. World J Gastroenterol.
20:5511–5518. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu YY, Ge C, Tian H, Jiang JY, Zhao FY,
Li H, Chen TY, Yao M and Li JJ: The transcription factor Ikaros
inhibits cell proliferation by downregulating ANXA4 expression in
hepatocellular carcinoma. Am J Cancer Res. 7:1285–1297.
2017.PubMed/NCBI
|
|
11
|
Wang H, Deng L, Cai M, Zhuang H, Zhu L,
Hao Y, Gao J, Liu J, Li X and Lin B: Annexin A4 fucosylation
enhances its interaction with NF-κB p50 and promotes tumor
progression of ovarian clear cell carcinoma. Oncotarget.
8:108093–108107. 2016. View Article : Google Scholar
|
|
12
|
Jeon YJ, Kim DH, Jung H, Chung SJ, Chi SW,
Cho S, Lee SC, Park BC, Park SG and Bae KH: Annexin A4 interacts
with the NF-kappaB p50 subunit and modulates NF-kappaB
transcriptional activity in a Ca2+-dependent manner.
Cell Mol Life Sci. 67:2271–2281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bolshakova A, Magnusson KE, Pinaev G and
Petukhova O: Functional compartmentalisation of NF-κB-associated
proteins in A431 cells. Cell Biol Int. 37:387–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fang Y, Chai Z, Wang D, Kuang T, Wu W and
Lou W: DNA-PKcs deficiency sensitizes the human hepatoma HepG2
cells to cisplatin and 5-fluorouracil through suppression of the
PI3K/Akt/NF-κB pathway. Mol Cell Biochem. 399:269–278. 2015.
View Article : Google Scholar
|
|
15
|
Basso F, Rocchetti F, Rodriguez S,
Nesterova M, Cormier F, Stratakis CA, Ragazzon B, Bertherat J and
Rizk-Rabin M: Comparison of the effects of PRKAR1A and PRKAR2B
depletion on signaling pathways, cell growth, and cell cycle
control of adrenocortical cells. Horm Metab Res. 46:883–888. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naugler WE and Karin M: NF-kappa B and
cancer-identifying targets and mechanisms. Curr Opin Genet Dev.
18:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Luo JL, Kamata H and Karin M: IKK/NF-kappa
B signaling: Balancing life and death-a new approach to cancer
therapy. J Clin Invest. 115:2625–2632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masuishi Y, Arakawa N, Kawasaki H, Miyagi
E, Hirahara F and Hirano H: Wild-Type p53 enhances annexin IV gene
expression in ovarian clear cell adenocarcinoma. FEBS J.
278:1470–1483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bykov VJ, Eriksson SE, Bianchi J and Wiman
KG: Targeting mutant p53 for efficient cancer therapy. Nat Rev
Cancer. 18:89–102. 2018. View Article : Google Scholar
|
|
20
|
Pereira A, Pérez-Medina T, Magrina JF,
Magtibay PM, Rodríguez-Tapia A, Peregrin I, Mendizabal E and
Ortiz-Quintana L: International federation of gynecology and
obstetrics staging classification for cancer of the ovary,
fallopian tube, and peritoneum: Estimation of survival in patients
with node-positive epithelial ovarian cancer. Int J Gynecol Cancer.
25:49–54. 2015. View Article : Google Scholar
|
|
21
|
Daly MB, Pilarski R, Berry M, Buys SS,
Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, et al:
NCCN guidelines insights: Genetic/Familial high-risk assessment:
Breast and ovarian, version 2.2017. J Natl Compr Canc Netw.
15:9–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang H, Tan M, Zhang S, Li X, Gao J, Zhang
D, Hao Y, Gao S, Liu J and Lin B: Expression and significance of
CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol
Sci. 16:3391–3404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iwamori M, Tanaka K, Kubushiro K, Lin B,
Kiguchi K, Ishiwata I, Tsukazaki K and Nozawa S: Alterations in the
glyolipid compo-sition and cellular properties of ovarian
carcinoma-derived RMG-1 cells on transfection of the α1,
2-fucosyltransferase gene. Cancer Sci. 96:26–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genom Res. 13:2498–2504. 2003. View Article : Google Scholar
|
|
25
|
Wade J, Armon S and McNally OM: Ovarian
clear cell carcinoma recurrence presenting as subcutaneous nodules.
Eur J Gynaecol Oncol. 37:575–577. 2016.PubMed/NCBI
|
|
26
|
Elvin JA, Chura J, Gay LM and Markman M:
Comprehensive genomic profiling (CGP) of ovarian clear cell
carcinomas (OCCC) identifies clinically relevant genomic
alterations (CRGA) and targeted therapy options. Gynecol Oncol Rep.
20:62–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-κB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
DiDonato JA, Mercurio F and Karin M: NF-κB
and the link between inflammation and cancer. Immunol Rev.
246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chariot A: The NF-kappaB-independent
functions of IKK subunits in immunity and cancer. Trends Cell Biol.
19:404–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rao P, Hayden MS, Long M, Scott ML, West
AP, Zhang D, Oeckinghaus A, Lynch C, Hoffmann A, Baltimore D and
Ghosh S: IkappaBbeta acts to inhibit and activate gene expres-sion
during the inflammatory response. Nature. 466:1115–1119. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wan F and Lenardo MJ: The nuclear
signaling of NF-kappaB: Current knowledge, new insights, and future
perspectives. Cell Res. 20:24–33. 2010. View Article : Google Scholar
|
|
32
|
Patel M, Horgan PG, McMillan DC and
Edwards J: NF-κB path-ways in the development and progression of
colorectal cancer. Transl Res. 197:43–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perkins ND: The diverse and complex roles
of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tilborghs S, Corthouts J, Verhoeven Y,
Arias D, Rolfo C, Trinh XB and van Dam PA: The role of nuclear
factor-kappa B signaling in human cervical cancer. Crit Rev Oncol
Hematol. 120:141–150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wei B, Guo C, Liu S and Sun MZ: Annexin A4
and cancer. Clin Chim Acta. 447:72–78. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yao H, Sun C, Hu Z and Wang W: The role of
annexin A4 in cancer. Front Biosci (Landmark Ed). 21:949–957. 2016.
View Article : Google Scholar
|
|
37
|
Kim A, Serada S, Enomoto T and Naka T:
Targeting annexin A4 to counteract chemoresistance in clear cell
carcinoma of the ovary. Expert Opin Ther Targets. 14:963–971. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hatoum D, Yagoub D, Ahadi A, Nassif NT and
McGowan EM: Annexin/S100A protein family regulation through
p14ARF-p53 activation: A role in cell survival and predicting
treatment outcomes in breast cancer. PLoS One. 12:e01699252017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perego P, Giarola M, Righetti SC, Supino
R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and
Zunino F: Association between cisplatin resistance and mutation of
p53 gene and reduced bax expression in ovarian carcinoma cell
systems. Cancer Res. 56:556–562. 1996.PubMed/NCBI
|
|
40
|
Matsuo Y, Tashiro H, Yanai H, Moriya T and
Katabuchi H: Clinicopathological heterogeneity in ovarian clear
cell adeno-carcinoma: A study on individual therapy practice. Med
Mol Morphol. 48:146–154. 2015. View Article : Google Scholar
|
|
41
|
Shi J, Xiao H, Li J, Zhang J, Li Y, Zhang
J, Wang X, Bai X, Tao K, Hu D and Guan H: Wild-Type p53-modulated
autophagy and autophagic fibroblast apoptosis inhibit hypertrophic
scar formation. Lab Invest. 98:1423–1437. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Galmarini CM, Kamath K, Vanier-Viornery A,
Hervieu V, Peiller E, Falette N, Puisieux A, Jordan AM and Dumontet
C: Drug resistance associated with loss of p53 involves extensive
alterations in microtubule composition and dynamics. Br J Cancer.
88:1793–1799. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meylan E, Dooley AL, Feldser DM, Shen L,
Turk E, Ouyang C and Jacks T: Requirement for NF-κB signaling in a
mouse model of lung adenocarcinoma. Nature. 462:104–107. 2009.
View Article : Google Scholar : PubMed/NCBI
|
